US EditionCostco To Sell Ozempic and Wegovy for $499 a Month
Costco offers discounted Ozempic and Wegovy at $499 monthly to improve access amid rising demand and insurance challenges, with over 7 million U.S. users currently on GLP-1 drugs.
- Costco pharmacies began selling a four-week supply of Ozempic and Wegovy for $499 out of pocket to members with prescriptions at more than 600 U.S. locations.
- Novo Nordisk said Friday that it cut 9,000 jobs this year and sells drugs via CVS and Walmart to expand legitimate access and compete with compounding pharmacies and medical spas.
- About 7 million Americans take a GLP-1 drug, with $71.7 billion spent in 2023, and new prescriptions increased over 700%, while 54% report affordability issues in the 2024 KFF survey.
- Doctors caution that Dr. Rekha Kumar said `This will definitely improve one of the issues with access,` but the Costco option does not resolve insurance or cost barriers.
- With more than 100 million visitors, Costco's rollout could introduce many new customers as only 13 states include the drugs in Medicaid coverage and Eli Lilly offers similar discounts.
31 Articles
31 Articles
This popular retailer now sells Ozempic with an additional discount
Some good news on the weight-loss front: Customers can now go to Costco to get Ozempic and Wegovy, brand-name injectable prescription drugs manufactured by drug maker Novo Nordisk, which contain the same active ingredient: semaglutide. The Danish pharmaceutical firm announced Friday that both are available at the big-box retailer’s pharmacies nationwide, for $499 for a month’s supply—the same price as sold in CVS, Walmart, and the company’s dire…
Costco Is Hawking Ozempic, Wegovy at Pharmacies
Costco is getting in on the surging popularity of weight-loss drugs. The warehouse chain is bringing the blockbuster drugs Ozempic and Wegovy to its pharmacies in the US, reports the New York Times . Members with a prescription can purchase a four-week supply of either drug for $499—roughly half the...
Coverage Details
Bias Distribution
- 48% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
